Veltassa(patiromer)
Veltassa (patiromer) is a small molecule pharmaceutical. Patiromer was first approved as Veltassa on 2015-10-21. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Veltassa (discontinued: Veltassa)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| veltassa | New Drug Application | 2024-10-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperkalemia | HP_0002153 | D006947 | E87.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Patiromer Sorbitex Calcium, Veltassa, Vifor Pharma | |||
| 9492476 | 2033-10-08 | U-1766 | |
| 9925212 | 2033-10-08 | U-1766 | |
| 11123363 | 2033-10-08 | U-1766 | |
| 8337824 | 2030-05-29 | DP | U-1766 |
| 8147873 | 2028-06-20 | DP | |
| 8282913 | 2027-05-29 | DP | |
| 8216560 | 2027-03-14 | U-1766 | |
| 7556799 | 2025-02-27 | U-1766 | |
| 8287847 | 2024-03-30 | U-1766 | |
| 8475780 | 2024-03-30 | U-1766 | |
| 8778324 | 2024-03-30 | U-1766 | |
| 8889115 | 2024-03-30 | U-1766 | |
| 10485821 | 2024-03-30 | U-1766 | |
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | 8 | 4 | 10 | 1 | 23 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 5 | 1 | 3 | 3 | 12 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 4 | 2 | 2 | 2 | 10 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 2 | 1 | 1 | 1 | 5 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | 1 | 1 | 2 | 1 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | — | 1 | — | 3 |
| Kidney transplantation | D016030 | — | — | — | — | — | 2 | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | 1 | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Patiromer |
| INN | patiromer calcium |
| Description | Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut.
|
| Classification | Small molecule |
| Drug class | polymers; antihyperlipidemic, thyromimetic derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107875 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09263 |
| UNII ID | 1FQ2RY5YHH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 681 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,814 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use